NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit

Core Viewpoint - A class action lawsuit has been filed against Novo Nordisk A/S for allegedly misleading investors regarding the company's phase 3 CagriSema study on obesity, specifically concerning the dosages provided to patients and the expected outcomes of the study [1][5]. Group 1: Lawsuit Details - The class action is on behalf of purchasers of Novo Nordisk securities between November 2, 2022, and December 19, 2024 [1]. - The lawsuit claims that defendants made overwhelmingly positive statements about the CagriSema study, including an expected minimum average weight loss of 25% for obesity patients [5]. - It is alleged that the defendants failed to disclose that the trial protocol was "flexible," allowing patients to modify their dosing throughout the trial, which misled investors [5]. Group 2: Legal Representation - Investors who purchased Novo Nordisk securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - The Rosen Law Firm encourages investors to select qualified counsel with a successful track record in securities class actions [4]. - A lead plaintiff must move the Court by March 25, 2025, to represent other class members in the litigation [3].